{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:10:41Z","timestamp":1790251841886,"version":"4.1.0"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1038\/s41375-026-03075-1","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:42:27Z","timestamp":1784637747000},"page":"2216-2222","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cytogenetics-based clinical trajectories in patients with MRD negativity post autologous transplant for multiple myeloma"],"prefix":"10.1038","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-4714","authenticated-orcid":false,"given":"Estefania Gauto","family":"Mariotti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5392-9284","authenticated-orcid":false,"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6890-969X","authenticated-orcid":false,"given":"Wilson","family":"Gonsalves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4342-364X","authenticated-orcid":false,"given":"Prashant","family":"Kapoor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3214-0203","authenticated-orcid":false,"given":"Francis","family":"Buadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9195-1589","authenticated-orcid":false,"given":"Nadine","family":"Abdallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9014-9658","authenticated-orcid":false,"given":"Moritz","family":"Binder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5335-9533","authenticated-orcid":false,"given":"Joselle","family":"Cook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7477-3004","authenticated-orcid":false,"given":"David","family":"Dingli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3853-5196","authenticated-orcid":false,"given":"Morie A.","family":"Gertz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8573-9434","authenticated-orcid":false,"given":"Taxiarchis","family":"Kourelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5651-1411","authenticated-orcid":false,"given":"Nelson","family":"Leung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1556-6416","authenticated-orcid":false,"given":"Yi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mustaqeem","family":"Siddiqui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8284-3495","authenticated-orcid":false,"given":"Ronald","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2210-2174","authenticated-orcid":false,"given":"Eli","family":"Muchtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rahma","family":"Warsame","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1792-5822","authenticated-orcid":false,"given":"Dragan","family":"Jevremovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Kyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5862-1833","authenticated-orcid":false,"given":"S. Vincent","family":"Rajkumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5074-8453","authenticated-orcid":false,"given":"Saurabh","family":"Zanwar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"3075_CR1","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"3075_CR2","doi-asserted-by":"crossref","unstructured":"Derman, BA, Fonseca R. Measurable residual disease and decision-making in multiple myeloma. Hematol Oncol Clin North Am. 2024;38:477\u201395.","DOI":"10.1016\/j.hoc.2023.12.009"},{"key":"3075_CR3","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1001\/jamaoncol.2016.3160","volume":"3","author":"NC Munshi","year":"2017","unstructured":"Munshi NC, Avet-Loiseau H, Rawstron AC, Owen RG, Child JA, Thakurta A, et al. Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis. JAMA Oncol. 2017;3:28\u201335.","journal-title":"JAMA Oncol"},{"key":"3075_CR4","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1200\/JCO-24-02020","volume":"43","author":"Q Shi","year":"2025","unstructured":"Shi Q, Paiva B, Pederson LD, Dimier N, Talpes E, Prior TJ, et al. Minimal residual disease-based end point for accelerated assessment of clinical trials in multiple myeloma: a pooled analysis of individual patient data from multiple randomized trials. J Clin Oncol. 2025;43:1289\u2013301.","journal-title":"J Clin Oncol"},{"key":"3075_CR5","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1182\/blood.2024024371","volume":"144","author":"O Landgren","year":"2024","unstructured":"Landgren O, Prior TJ, Masterson T, Heuck C, Bueno OF, Dash AB, et al. EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma. Blood. 2024;144:359\u201367.","journal-title":"Blood"},{"key":"3075_CR6","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1056\/NEJMoa2505133","volume":"393","author":"A Perrot","year":"2025","unstructured":"Perrot A, Lambert J, Hulin C, Pieragostini A, Karlin L, Arnulf B, et al. Measurable residual disease-guided therapy in newly diagnosed myeloma. N Engl J Med. 2025;393:425\u201337.","journal-title":"N Engl J Med"},{"key":"3075_CR7","doi-asserted-by":"crossref","unstructured":"Zanwar S, Rajkumar SV. Measurable residual disease assessment in multiple myeloma. Leukemia 2026;40:25\u20138.","DOI":"10.1038\/s41375-025-02830-0"},{"key":"3075_CR8","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien ML, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364.","journal-title":"Blood"},{"key":"3075_CR9","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1200\/JCO.19.01231","volume":"38","author":"B Paiva","year":"2020","unstructured":"Paiva B, Puig N, Cedena MT, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales MB, et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. J Clin Oncol. 2020;38:784\u201392.","journal-title":"J Clin Oncol"},{"key":"3075_CR10","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","volume":"137","author":"I Goicoechea","year":"2021","unstructured":"Goicoechea I, Puig N, Cedena MT, Burgos L, Cord\u00f3n L, Vidriales MB, et al. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood. 2021;137:49\u201360.","journal-title":"Blood"},{"key":"3075_CR11","doi-asserted-by":"publisher","first-page":"e890","DOI":"10.1016\/S2352-3026(23)00236-3","volume":"10","author":"LJ Costa","year":"2023","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN, et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023;10:e890\u2013e901.","journal-title":"Lancet Haematol"},{"key":"3075_CR12","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for multiple myeloma: A Report From International Myeloma Working Group. J Clin Oncol. 2015;33:2863\u20139.","journal-title":"J Clin Oncol"},{"key":"3075_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-022-00611-x","volume":"12","author":"NH Abdallah","year":"2022","unstructured":"Abdallah NH, Binder M, Rajkumar SV, Greipp PT, Kapoor P, Dispenzieri A, et al. A simple additive staging system for newly diagnosed multiple myeloma. Blood Cancer J. 2022;12:21.","journal-title":"Blood Cancer J"},{"key":"3075_CR14","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1200\/JCO-24-01893","volume":"43","author":"H Avet-Loiseau","year":"2025","unstructured":"Avet-Loiseau H, Davies FE, Samur MK, Corre J, D\u2019Agostino M, Kaiser MF, et al. International Myeloma Society\/International Myeloma Working Group consensus recommendations on the definition of high-risk multiple myeloma. J Clin Oncol. 2025;43:2739\u201351.","journal-title":"J Clin Oncol"},{"key":"3075_CR15","doi-asserted-by":"publisher","first-page":"2889","DOI":"10.1200\/JCO.21.02228","volume":"40","author":"RM de Tute","year":"2022","unstructured":"de Tute RM, Pawlyn C, Cairns DA, Davies FE, Menzies T, Rawstron A, et al. Minimal residual disease after autologous stem-cell transplant for patients with myeloma: prognostic significance and the impact of lenalidomide maintenance and molecular risk. J Clin Oncol. 2022;40:2889\u20132900.","journal-title":"J Clin Oncol"},{"key":"3075_CR16","doi-asserted-by":"publisher","first-page":"e221","DOI":"10.1016\/j.clml.2020.01.001","volume":"20","author":"C Kunacheewa","year":"2020","unstructured":"Kunacheewa C, Lee HC, Patel K, Thomas S, Amini B, Srour S, et al. Minimal residual disease negativity does not overcome poor prognosis in high-risk multiple myeloma: a single-center retrospective study. Clin Lymphoma Myeloma Leuk. 2020;20:e221\u2013e238.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"3075_CR17","doi-asserted-by":"publisher","first-page":"3509","DOI":"10.1182\/bloodadvances.2020002218","volume":"4","author":"N Abdallah","year":"2020","unstructured":"Abdallah N, Greipp P, Kapoor P, Gertz MA, Dispenzieri A, Baughn LB, et al. Clinical characteristics and treatment outcomes of newly diagnosed multiple myeloma with chromosome 1q abnormalities. Blood Adv. 2020;4:3509\u201319.","journal-title":"Blood Adv"},{"key":"3075_CR18","doi-asserted-by":"publisher","first-page":"2754","DOI":"10.3324\/haematol.2021.278888","volume":"106","author":"N Weinhold","year":"2021","unstructured":"Weinhold N, Salwender HJ, Cairns DA, Raab MS, Waldron G, Blau IW, et al. Chromosome 1q21 abnormalities refine outcome prediction in patients with multiple myeloma - a meta-analysis of 2,596 trial patients. Haematologica. 2021;106:2754\u20138.","journal-title":"Haematologica"},{"key":"3075_CR19","doi-asserted-by":"publisher","first-page":"2353","DOI":"10.1182\/blood.2024027686","volume":"145","author":"E Terpos","year":"2025","unstructured":"Terpos E, Malandrakis P, Ntanasis-Stathopoulos I, Kostopoulos IV, Eleutherakis-Papaiakovou E, Kanellias N, et al. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post-ASCT in myeloma. Blood. 2025;145:2353\u201360.","journal-title":"Blood"},{"key":"3075_CR20","doi-asserted-by":"crossref","unstructured":"Bal S, Ravi G, Dhakal B, Callander NS, Medvedova E, Dholaria B, et al. Distinct trajectory of measurable residual disease in t(11;14) myeloma treated with quadruplet therapy. Blood. 2026;147:1857\u201362.","DOI":"10.1182\/blood.2025031952"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03075-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03075-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03075-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:43:37Z","timestamp":1790250217000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-026-03075-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3075"],"URL":"https:\/\/doi.org\/10.1038\/s41375-026-03075-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-8586124\/v1","asserted-by":"object"}]},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"assertion":[{"value":"12 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Estefania Gauto Mariotti: none declared. Shaji Kumar: Takeda, Consultancy (Includes expert testimony): Yes, Research Funding: Yes, Celgene, Consultancy (Includes expert testimony): Yes, Research Funding: Yes, Sanofi, Consultancy (Includes expert testimony): Yes, Merck, Consultancy (Includes expert testimony): Yes, Janssen, Consultancy (Includes expert testimony): Yes, Research Funding: Yes, KITE, Consultancy (Includes expert testimony): Yes, Research Funding: Yes, Oncopeptides, Consultancy (Includes expert testimony): Yes. Novartis, Consultancy (Includes expert testimony): Yes. MedImmune\/AstraZeneca, Consultancy (Includes expert testimony): Yes, Research Funding: Yes, AbbVie, Consultancy (Includes expert testimony): Yes, Research Funding: Yes, Roche, Consultancy (Includes expert testimony): Yes, Adaptive, Consultancy (Includes expert testimony): Yes, Research Funding: Yes. Wilson Gonsalves: None declared. Prashant Kapoor: Karyopharm, Research Funding: Yes, AstraZeneca Honoraria: Yes, Sorrento Therapeutics, Research Funding: Yes, MustangBio, Honoraria: Yes, BeiGene;, Honoraria: Yes, GlaxoSmithKline, Research Funding: Yes, Bristol-Myers Squibb\/Celgene, Research Funding: Yes, Research Funding: Yes, Honoraria: Yes, Ichnos Sciences, Research Funding: Yes, Takeda Research Funding: Yes, Honoraria: Yes, Abbvie Research Funding: Yes, Honoraria: Yes, Amgen Research Funding: Yes. Francis Buadi: None declared. Suzanne Hayman: None declared, Nadine Abdallah: None declared, Moritz Binder: None declared, Joselle Cook: None declared. Angela Dispenzieri: Pfizer, Research Funding: Yes; Celgene, Research Funding: Yes; Takeda, Research Funding: Yes; Alnylam, Research Funding: Yes; ABBVIE, Research Funding: Yes; Janssen, Consultancy (Includes expert testimony): Yes, Research Funding: Yes. David Dingli: Apellis, Consultancy (Includes expert testimony): Yes, Research Funding: Yes, MSD, Consultancy (Includes expert testimony): Yes, Genentech, Consultancy (Includes expert testimony): Yes, Sorrento, Consultancy (Includes expert testimony): Yes, Janssen, Consultancy (Includes expert testimony): Yes, BMS, Consultancy (Includes expert testimony): Yes, Sano, Consultancy (Includes expert testimony): Yes; K36 Therapeutics, Research Funding: Yes, Regeneron, Consultancy (Includes expert testimony): Yes, Alexion, Consultancy (Includes expert testimony): Yes, Novartis, Consultancy (Includes expert testimony): Yes. Morie Gertz: Alexion, Honoraria: Yes; IOnis\/Alkcea, Consultancy (Includes expert testimony): Yes; Jassen, Consultancy (Includes expert testimony): Yes, DAVA oncology, Honoraria: Yes, Abbvie & Arcellex, Consultancy (Includes expert testimony): Yes; Sanofi, Consultancy (Includes expert testimony): Yes, ; astra Zeneca, Honoraria: Yes, alnylyum, Honoraria: Yes; Johnson & Johnson, Consultancy (Includes expert testimony): Yes, Honoraria: Yes. Taxiarchis Kourelis: None declared, Nelson Leung: None declared. Yi Lin: Bristol-Myers Squibb, Consultancy (Includes expert testimony): Yes, Research Funding: Yes, Caribou Biosciences, Consultancy (Includes expert testimony): Yes, Kite\/Gilead, Consultancy (Includes expert testimony): Yes; Pfizer, Consultancy (Includes expert testimony): Yes, Research Funding: Yes; Genentech, Consultancy (Includes expert testimony): Yes; Regeneron, Consultancy (Includes expert testimony): Yes; Nektar, Consultancy (Includes expert testimony): Yes; Tessera, Consultancy (Includes expert testimony): Yes, Sanofi, Consultancy (Includes expert testimony): Yes; NexImmune, Consultancy (Includes expert testimony): Yes, Adicet Bio, Consultancy (Includes expert testimony): Yes, Chimeric Therapeutics, Consultancy (Includes expert testimony): Yes, Fosun Kite, Consultancy (Includes expert testimony): Yes, Legend Biotech, Vineti, Consultancy (Includes expert testimony): Yes. Eli Muchtar: None declared. Rahma Warsame: Third bridge, Consultancy (Includes expert testimony): Yes, Takeda, Consultancy (Includes expert testimony): Yes, employment in the past 24 Sanofi, Honoraria: Yes. Dragan Jevremovic: None declared, Robert Kyle: None declared, Ronald Go: None declared, Mustaqeem Siddiqui: None declared. S. Vincent Rajkumar: None declared, Saurabh Zanwar: None declared.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}